Navigation Links
Post-Hoc Data Show Daily Activity Participation, Independence and Sleep Quality Improved in Adults with Moderate to Severe Rheumatoid Arthritis After Treatment with ORENCIA(R) (Abatacept)
Date:11/12/2007

eline 0.61 vs. 1.47, respectively; p-value less than 0.01). Secondary endpoints included ACR 20, 50, and 70 over time, major clinical response (45 percent for ORENCIA plus MTX), DAS at one year (42.5 percent vs. 9.9 percent, respectively; p-value less than 0.001), joint space narrowing (mean change from baseline 0.46 vs. 0.97, respectively; p-value less than 0.01), total Sharp scores at one year (mean change from baseline 1.07 vs. 2.43, respectively; p-value less than 0.01), and SF-36 through one year (mean change from baseline 8.44 vs. 5.28, respectively; p-value less than 0.001). ATTAIN was a Phase III multi-center, randomized, double-blind, placebo-controlled trial with 391 patients treated at baseline who had active RA despite anti-TNF therapy (389 included in efficacy analyses). The study was double-blind through six months, followed by an ongoing, open-label, long- term extension study. A total of 217 (from the original 256) patients in the group treated with ORENCIA entered the long-term extensions study. Additional DMARDs, NSAIDs, and aspirin were added and/or adjusted at the discretion of the investigator in the long-term extension study. Primary reasons for discontinuation in the long-term extension studies were adverse events and lack of efficacy

Primary endpoints were ACR 20 at six months ORENCIA vs. placebo (50.4 placebo vs. 19.5 percent, respectively; p-value less than 0.001) and improvement in HAQ-DI at six months (47.3 percent vs. 23.3 percent, respectively; p-value less than 0.001). Secondary endpoints were ACR 20, 50, and 70 over time, DAS28 at six months (DAS28 less than or equal to 3.2, 18 percent and DAS28 less than 2.6; 11.1 percent) and SF-36 at six months (55.6 percent vs. 31.6 percent, respectively; p-value less than 0.001). In five clinical trials, the most serious adverse reactions were serious infections (3 percent ORENCIA(R) (abatacept) vs. 1.9 percent placebo) and malignancies (1.3 percent ORENCIA vs. 1.1 percent placebo). The mos
'/>"/>

SOURCE Bristol-Myers Squibb Company
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. New Phase 3 Study in Treatment-Naive Adults with HIV Evaluates Efficacy and Safety of Once-Daily PREZISTA(TM)/ritonavir vs. KALETRA(R) as Part of HIV Combination Therapy
2. New Data Published in Neurology Show Once-Daily Lamictal XR Significantly Reduced Partial Seizures in Patients with Epilepsy
3. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
4. Potent Hepatitis C Virus Inhibitors Show Efficacy and Potential for Once Daily Dosing in Preclinical Studies
5. ISTA Pharmaceuticals Presents Results from Two Phase III Clinical Trials of Xibrom(TM) QD (Once-daily) Formulation at the American Academy of Ophthalmology Annual Meeting
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. R7128 Demonstrates Safety and Potent Antiviral Activity in HCV-Infected Patients
8. Oritavancin Demonstrates Superior In Vitro Activity to Vancomycin and Metronidazole Against C. Difficile Bacteria
9. Targanta Presents First Data Demonstrating In Vitro Activity and In Vivo Efficacy of Prodrugs in Osteomyelitis Models
10. Oritavancin Demonstrates Potent and Rapid In Vitro Activity Against MRSA, VRE and Other Strains of Resistant Bacteria
11. Proteolix Initiates Multicenter Open-label Study of the Safety and Activity of Carfilzomib in Subjects With Relapsed Solid Tumors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... , Aug. 21, 2014  AliveCor, Inc. ... Drug Administration (FDA) has granted the company ... fibrillation (AFib), the most common form of ... instantly detects if patients are experiencing AFib ... the mobile phone based AliveCor® Heart Monitor, ...
(Date:8/21/2014)... , Aug. 21, 2014   Royal Philips ... today announced it has received 510(k) clearance from ... its precision planning application for Transcatheter Aortic-Valve Implantation ... application provides interventionalists with pre-procedural, high-precision positioning to ... TAVI planning application is available as part of ...
(Date:8/20/2014)... 20, 2014 Northstar Global Business Services, ... months of hard work from many talented specialists, ... formulation and package design.  The new formulation for ... into the product due to overwhelming evidence of ... Snorenz Nighttime will also include these vitamins, as ...
Breaking Medicine Technology:AliveCor Receives First FDA Clearance to Detect a Serious Heart Condition in an ECG on a Mobile Device 2Philips receives FDA 510(k) Clearance for TAVI Precision Treatment Planning Application 2Philips receives FDA 510(k) Clearance for TAVI Precision Treatment Planning Application 3Northstar completes the first phase of its new retail strategy and prepares to ship reformulated Snorenz with all new packaging 2
... Reported in 4Q 2007 -, LA JOLLA, ... TPTX ) today announced that it has completed,enrollment ... for the treatment,of acute migraine headache. Tezampanel is ... non-vascular and non-serotonergic,approach to the management of pain ...
... 3 trial of Genasense(R) seeks to confirm benefit in melanoma -- ... Company regains compliance for NASDAQ Global Markets listing; Genta common stock ... program for Genasense will continue ... during Phase 3 trial ...
Cached Medicine Technology:TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache 2TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache 3TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache 4Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights 2Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights 3Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights 4Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights 5Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights 6Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights 7Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights 8
(Date:8/21/2014)... chronic kidney disease patients may be a strong indicator ... in the Journal of the American Society of ... Hopkins Bloomberg School of Public Health assert that coronary ... atherosclerosis in predicting the risk of heart disease among ... all patients with chronic kidney disease (CKD) die from ...
(Date:8/21/2014)... (PRWEB) August 21, 2014 Pulmonary ... with an Education Forum for PH patients and ... Who:    The Pulmonary Hypertension Association – the ... find ways to prevent and cure pulmonary hypertension ... affects the functioning of the heart and can ...
(Date:8/21/2014)... Researchers have pinpointed the environmental source of fungal infections ... for decades. It literally grows on trees. , The ... 13-year-old girl, who spent the summer gathering soil and ... by infections of the fungus named Cryptococcus gattii ... which encompasses a number of species including C. ...
(Date:8/21/2014)... -- Black mothers are less likely than white moms ... why: Hospitals in neighborhoods with many black residents do ... more white residents, a U.S. government study finds. ... in medical centers where the black population is higher ... Control and Prevention reported Thursday. These practices include ...
(Date:8/21/2014)... THURSDAY, Aug. 21, 2014 (HealthDay News) -- Among seniors, ... suggests. The study involved more than 2,500 people, aged ... the study and again two, six and eight years later. ... in the person,s risk of death during the study period, ... and effect, researchers led by Sharon Christ of Purdue University ...
Breaking Medicine News(10 mins):Health News:Measuring calcium buildup to predict heart disease in those with chronic kidney disease 2Health News:Pulmonary Hypertension Association Goes On the Road to Houston With an Education Forum for PH Patients and Families to Help Fight Rare Lung Disease 2Health News:Pulmonary Hypertension Association Goes On the Road to Houston With an Education Forum for PH Patients and Families to Help Fight Rare Lung Disease 3Health News:Fungus deadly to AIDS patients found to grow on trees 2Health News:Racial Disparities in Breast-Feeding May Start With Hospitals, Study Suggests 2Health News:Failing Vision Tied to Shorter Lifespans for Seniors 2
... Interim Results from National Chronic Disease ... ... participants in the Diabetes Ten City Challenge (DTCC) improved across,all ... of,the program, the American Pharmacists Association (APhA) Foundation,announced today., ...
... CHAPEL HILL, N.C., March 12 R&D structure ... is,essential to pharmaceutical companies. In a competitive market ... process increases -- the need to have an,optimized ... Discover the best-suited organizational structure that promotes rapid,growth, ...
... Millennium,Pharmaceuticals, Inc. (Nasdaq: MLNM ) ... Annual Lehman Brothers Global Healthcare Conference will ... visiting the Investors section of the,Company,s website, ... ), The presentation will include ...
... XTNT ) today announced that Gregory D. Casciaro, ... Company,s 28th Annual,Health Care Conference on Tuesday, March 18, ... at the Boston Marriot Copley Place in Boston, MA., ... device company focused on developing and,commercializing innovative customizable drug ...
... its ongoing effort to,give consumers information to improve ... four area hospitals have been,selected as Blue Distinction ... Distinction(R) is a nationwide program created to give ... and to work with their,health care providers to ...
... 12 Accuray,Incorporated (Nasdaq: ARAY ), a global ... company received the 2008 North American Medical,Devices Product of ... Sullivan, for its CyberKnife(R) Robotic Radiosurgery System., The ... is presented each,year to the company that has demonstrated ...
Cached Medicine News:Health News:Diabetes Ten City Challenge Collaborative Model Shows Improved Patient Health Across Key Clinical Indicators 2Health News:Diabetes Ten City Challenge Collaborative Model Shows Improved Patient Health Across Key Clinical Indicators 3Health News:Diabetes Ten City Challenge Collaborative Model Shows Improved Patient Health Across Key Clinical Indicators 4Health News:R&D Quality Excellence: Proven Tactics Optimize the R&D Quality Organizations of Pharmaceutical and Biotech Industries 2Health News:Eleventh Annual Lehman Brothers Global Healthcare Conference to Webcast Millennium Presentation 2Health News:Independence Blue Cross Announces Blue Distinction Centers for Complex and Rare Cancers(SM) in Philadelphia 2Health News:Independence Blue Cross Announces Blue Distinction Centers for Complex and Rare Cancers(SM) in Philadelphia 3Health News:Accuray's CyberKnife System Receives 2008 North American Medical Devices Product of the Year Award From Frost & Sullivan 2Health News:Accuray's CyberKnife System Receives 2008 North American Medical Devices Product of the Year Award From Frost & Sullivan 3
... Line ULTRA® Suctionaid® tracheostomy tubes provide an ... secretions from above the tracheostomy tube cuff. ... tracheostomy tubes provide an additional lumen to ... the tracheostomy tube cuff helping to reduce ...
Fenestrations allow your patients to vocalize when cuff is deflated...
The all silicone construction of the shaft and neck flange provides the utmost in patient comfort. , ,The Aire-Cuf® tracheostomy tube offers a more traditional and familiar air-filled cuff desig...
... Built-in 15 mm ISO termination for ... inner cannula in place. , ,Clearly ... inner cannula system , ,The Portex® ... constructed of siliconized polyvinyl chloride, providing a ...
Medicine Products: